Show simple item record

dc.contributor.authorToth, R
dc.contributor.authorScherer, D
dc.contributor.authorKelemen, LE
dc.contributor.authorRisch, A
dc.contributor.authorHazra, A
dc.contributor.authorBalavarca, Y
dc.contributor.authorIssa, J-PJ
dc.contributor.authorMoreno, V
dc.contributor.authorEeles, RA
dc.contributor.authorOgino, S
dc.contributor.authorWu, X
dc.contributor.authorYe, Y
dc.contributor.authorHung, RJ
dc.contributor.authorGoode, EL
dc.contributor.authorUlrich, CM
dc.contributor.authorOCAC, CORECT, TRICL, ELLIPSE, DRIVE, and GAME-ON consortia,
dc.date.accessioned2018-07-26T08:41:27Z
dc.date.issued2017-06-01
dc.identifier.citationCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2017, 26 (6), pp. 816 - 825
dc.identifier.issn1055-9965
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2153
dc.identifier.eissn1538-7755
dc.identifier.doi10.1158/1055-9965.epi-16-0728
dc.description.abstractBackground: Epigenetic disturbances are crucial in cancer initiation, potentially with pleiotropic effects, and may be influenced by the genetic background.Methods: In a subsets (ASSET) meta-analytic approach, we investigated associations of genetic variants related to epigenetic mechanisms with risks of breast, lung, colorectal, ovarian and prostate carcinomas using 51,724 cases and 52,001 controls. False discovery rate-corrected P values (q values < 0.05) were considered statistically significant.Results: Among 162,887 imputed or genotyped variants in 555 candidate genes, SNPs in eight genes were associated with risk of more than one cancer type. For example, variants in BABAM1 were confirmed as a susceptibility locus for squamous cell lung, overall breast, estrogen receptor (ER)-negative breast, and overall prostate, and overall serous ovarian cancer; the most significant variant was rs4808076 [OR = 1.14; 95% confidence interval (CI) = 1.10-1.19; q = 6.87 × 10-5]. DPF1 rs12611084 was inversely associated with ER-negative breast, endometrioid ovarian, and overall and aggressive prostate cancer risk (OR = 0.93; 95% CI = 0.91-0.96; q = 0.005). Variants in L3MBTL3 were associated with colorectal, overall breast, ER-negative breast, clear cell ovarian, and overall and aggressive prostate cancer risk (e.g., rs9388766: OR = 1.06; 95% CI = 1.03-1.08; q = 0.02). Variants in TET2 were significantly associated with overall breast, overall prostate, overall ovarian, and endometrioid ovarian cancer risk, with rs62331150 showing bidirectional effects. Analyses of subpathways did not reveal gene subsets that contributed disproportionately to susceptibility.Conclusions: Functional and correlative studies are now needed to elucidate the potential links between germline genotype, epigenetic function, and cancer etiology.Impact: This approach provides novel insight into possible pleiotropic effects of genes involved in epigenetic processes. Cancer Epidemiol Biomarkers Prev; 26(6); 816-25. ©2017 AACR.
dc.formatPrint-Electronic
dc.format.extent816 - 825
dc.languageeng
dc.language.isoeng
dc.publisherAMER ASSOC CANCER RESEARCH
dc.rights.urihttps://www.rioxx.net/licenses/all-rights-reserved
dc.subjectOCAC, CORECT, TRICL, ELLIPSE, DRIVE, and GAME-ON consortia
dc.subjectHumans
dc.subjectNeoplasms
dc.subjectRisk Factors
dc.subjectFemale
dc.subjectMale
dc.subjectGenetic Variation
dc.subjectEpigenomics
dc.titleGenetic Variants in Epigenetic Pathways and Risks of Multiple Cancers in the GAME-ON Consortium.
dc.typeJournal Article
dcterms.dateAccepted2016-12-19
rioxxterms.versionofrecord10.1158/1055-9965.epi-16-0728
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2017-06
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
pubs.issue6
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Oncogenetics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Oncogenetics
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Oncogenetics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Oncogenetics
pubs.publication-statusPublished
pubs.volume26
pubs.embargo.termsNot known
icr.researchteamOncogenetics
dc.contributor.icrauthorEeles, Rosalind


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record